Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

ConclusionsSOF/VEL for 12  weeks is efficacious and well-tolerated by chronic HCV-infected patients with compensated liver disease in Taiwan.
Source: Hepatology International - Category: Infectious Diseases Source Type: research